Nyxoah Closes $95M Public Offering, Securing Critical Funding Amid Going Concern Doubts
Summary
Nyxoah announced the closing of its underwritten public offering, raising approximately $95 million in gross proceeds by selling 55.2 million ordinary shares at $1.72 per share. This follows the announcement and pricing of the offering last week, and an SEC filing on June 8th confirming its completion. The capital infusion is critical for the company's liquidity and continued operations, addressing the severe financial distress and "going concern" warnings highlighted in recent filings. The offering was priced at $1.72, which is above the current market price of $1.31. The company intends to use the net proceeds for expanding U.S. commercialization, R&D, and general corporate purposes, including debt repayment.
At the time of this announcement, NYXH was trading at $1.31 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $130.9M. The 52-week trading range was $1.26 to $8.59. This news item was assessed with positive market sentiment and an importance score of 8 out of 10. Source: GlobeNewswire.